دورية أكاديمية
National trends in prescription drug expenditures and projections for 2023.
| العنوان: | National trends in prescription drug expenditures and projections for 2023. |
|---|---|
| المؤلفون: | Tichy EM; Mayo Clinic, Rochester, MN, USA., Hoffman JM; St. Jude Children's Research Hospital, Memphis, TN, USA., Tadrous M; St. Michael's Hospital, Toronto, Canada.; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada., Rim MH; Northwestern Medicine, Chicago, IL, USA., Suda KJ; Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Department of Veterans Affairs, Pittsburgh, PA.; Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Cuellar S; College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA., Clark JS; Michigan Medicine, University of Michigan, Ann Arbor, MI.; University of Michigan College of Pharmacy, Ann Arbor, MI, USA., Newell MK; Supplier Services, IQVIA, Plymouth Meeting, PA, USA., Schumock GT; College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA. |
| المصدر: | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2023 Jul 07; Vol. 80 (14), pp. 899-913. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium: Internet ISSN: 1535-2900 (Electronic) Linking ISSN: 10792082 NLM ISO Abbreviation: Am J Health Syst Pharm Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2019-> : [Oxford] : Oxford University Press Original Publication: Bethesda, MD : The Society, c1995- |
| مواضيع طبية MeSH: | Prescription Drugs* , Biosimilar Pharmaceuticals* , COVID-19*/epidemiology , Antineoplastic Agents*, Humans ; United States ; Health Expenditures ; Pandemics ; Drug Costs |
| مستخلص: | Purpose: To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2023 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods: Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2023 were reviewed, including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, diabetes medications, generics, COVID-19 pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2023 were based on a combination of quantitative analyses and expert opinion. Results: In 2022, overall pharmaceutical expenditures in the US grew 9.4% compared to 2021, for a total of $633.5 billion. Utilization (a 5.9% increase), price (a 1.7% increase) and new drugs (a 1.8% increase) drove this increase. Adalimumab was the top-selling drug in 2022, followed by semaglutide and apixaban. Drug expenditures were $37.2 billion (a 5.9% decrease) and $116.9 billion (a 10.4% increase) in nonfederal hospitals and clinics, respectively. In clinics, new products and increased utilization growth drove growth, with a small impact from price changes. In nonfederal hospitals, a drop in utilization led to a decrease in expenditures, with price changes and new drugs contributing to growth in spending. Several new drugs that will influence spending have been or are expected to be approved in 2023. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion: For 2023, we expect overall prescription drug spending to rise by 6.0% to 8.0%, whereas in clinics and hospitals we anticipate increases of 8.0% to 10.0% and 1.0% to 3.0%, respectively, compared to 2022. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending. (© American Society of Health-System Pharmacists 2023. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| فهرسة مساهمة: | Keywords: COVID-19; biosimilars; cancer drugs; diabetes therapies; drug expenditures; pandemic; public policy |
| المشرفين على المادة: | 0 (Prescription Drugs) 0 (Biosimilar Pharmaceuticals) 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20230424 Date Completed: 20230710 Latest Revision: 20231116 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1093/ajhp/zxad086 |
| PMID: | 37094296 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1535-2900 |
|---|---|
| DOI: | 10.1093/ajhp/zxad086 |